Leonard Zehr, Author at BioTuesdays

Feature

Rani developing technology for oral delivery of injectable biologics

Rani Therapeutics (NASDAQ:RANI) is developing a disruptive technology to solve the problem of converting biologic injectable drugs, including antibodies, peptides and proteins, into oral therapies with its RaniPill that...

December 7, 2021

Feature

Fabian Gerlinghaus talks up the power of the Cellares Cell Shuttle

As a co-founder and CEO of closely-held Cellares, which is pioneering an automated approach to cell therapy manufacturing, Fabian Gerlinghaus, an aerospace engineer by training, made the switch to biotech eight years...

November 30, 2021

Feature

Genocea’s pioneering next generation neoantigen targets T-cell therapy

Genocea Biosciences (NASDAQ:GNCA) is on a mission to make better cancer immunotherapies for patients, beginning with better target discovery.

November 23, 2021

Executive Moves

Labster names Hope Frank as CMO

Hope Frank Closely-held Labster, a virtual learning platform for students, named Hope Frank as chief marketing officer as part of its continued mission to bring accessible and transformative STEM education (science...

November 17, 2021

Feature

Titan Pharmaceuticals, UW treating chronic itch with ProNeura implant

As a research assistant professor at the Department of Pharmacology at the University of Washington, Dr. Ben Land, Ph.D. is broadly interested in how cannabinoids and opioids mediate pain and reward. But in a...

November 9, 2021

Feature

NervGen unleashing nervous system to heal itself

NervGen Pharma (TSX-V:NGEN; OTCQX:NGENF) is developing a new class of drugs that repairs damage to the nervous system and restores motor, sensory and cognitive function to diseases where there are currently no approved...

November 2, 2021

Feature

Lanier Biotherapeutics to develop first-in-class biologics portfolio for specialty diseases

Recently launched Lanier Biotherapeutics is developing specialty biologic treatments for indications in multifunctional retina, dermatology and Type 2 inflammation diseases.

October 26, 2021

Feature

Aligos Therapeutics targeting functionally curative HBV regimen

Even though a number of antiviral medications are in use to treat chronic hepatitis B virus (HBV) infections, Aligos Therapeutics (NASDAQ:ALGS) is going one step further with a portfolio of drug candidates in clinical...

October 19, 2021

Feature

Acasti Pharma transitions to orphan diseases from cardiovascular

After a failed Phase 3 trial in August 2020 with its CaPre lead drug candidate for patients with severe hypertriglyceridemia, Acasti Pharma (NASDAQ, TSXV:ACST) has transitioned into the rare and orphan disease sector...

October 12, 2021

Feature

ContraFect advancing new modality for antibiotic-resistant infections

In a bid to counter the next great health crisis, ContraFect (NASDAQ:CFRX) is in late-stage development of a new modality to treat life-threatening and antibiotic-resistant infections, using direct lytic agents (DLAs).

October 5, 2021

Author - Leonard Zehr

Rani developing technology for oral delivery of injectable biologics

Fabian Gerlinghaus talks up the power of the Cellares Cell Shuttle

Genocea’s pioneering next generation neoantigen targets T-cell therapy

Labster names Hope Frank as CMO

Titan Pharmaceuticals, UW treating chronic itch with ProNeura implant

NervGen unleashing nervous system to heal itself

Lanier Biotherapeutics to develop first-in-class biologics portfolio for specialty diseases

Aligos Therapeutics targeting functionally curative HBV regimen

Acasti Pharma transitions to orphan diseases from cardiovascular

ContraFect advancing new modality for antibiotic-resistant infections

Subscribe